Loading...
Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer
Background: Non-small cell lung cancer (NSCLC) commonly presents at advanced stage. We previously reported systemic treatment uptake in stage IV NSCLC climbing from 55% (2009–2012) to 62% (2015–2017). Since then, first-line immunotherapy and 2nd/3rd generation tyrosine kinase inhibitors (TKIs) have...
Na minha lista:
| Udgivet i: | Curr Oncol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7816185/ https://ncbi.nlm.nih.gov/pubmed/33704175 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/curroncol28010008 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|